Justin West is a physician and father of three. His youngest son, Andrew, was diagnosed with KCNT1-related epilepsy at 9 months of age. He is director of clinical medicine at the KCNT1 Epilepsy Foundation, working with researchers and industry to identify and evaluate potential therapeutics.
Justin West
President and director of clinical medicine
KCNT1 Epilepsy Foundation
From this contributor
Progress amid setbacks in drug trials for rare forms of epilepsy: Q&A with Justin West
Despite grave side effects, it’s vital to keep developing treatments for rare genetic forms of childhood epilepsy, says West, president of the KCNT1 Epilepsy Foundation and father of a son with the condition.
Progress amid setbacks in drug trials for rare forms of epilepsy: Q&A with Justin West
Explore more from The Transmitter
What leeches reveal about movement
Lidia Szczupak turned to the animals to explore how the nervous system coordinates movement.
What leeches reveal about movement
Lidia Szczupak turned to the animals to explore how the nervous system coordinates movement.
Redefining underrepresentation in global neuroscience
Shifting the focus of equity initiatives from identity categories to structural barriers can reveal overlooked challenges and increase support and participation worldwide.
Redefining underrepresentation in global neuroscience
Shifting the focus of equity initiatives from identity categories to structural barriers can reveal overlooked challenges and increase support and participation worldwide.
Scientific talent is global. Access to the world’s scientific stage is not.
Neuroscience in Chile, and across Latin America, does not lack talent or ideas, but the systems that make science visible—prestigious journals, conferences and networks—increasingly price its researchers out.
Scientific talent is global. Access to the world’s scientific stage is not.
Neuroscience in Chile, and across Latin America, does not lack talent or ideas, but the systems that make science visible—prestigious journals, conferences and networks—increasingly price its researchers out.